All 000-278 dump questions are provided here for download

On the off chance that you want to, breeze through 000-278 test with simply perusing course books, you are incorrect. There are a few interesting inquiries that you never see in 000-278 course reading. We have 000-278 braindumps that contains every one of the precarious inquiries that you will see at test screen. Download 100 percent free PDF Questions before you register for full 000-278 Question Bank documents.

Exam Code: 000-278 Practice test 2022 by Killexams.com team
IBM Worklight V6.0 Mobile Application Development
IBM Application health
Killexams : IBM Application health - BingNews https://killexams.com/pass4sure/exam-detail/000-278 Search results Killexams : IBM Application health - BingNews https://killexams.com/pass4sure/exam-detail/000-278 https://killexams.com/exam_list/IBM Killexams : Medical Imaging, Powered by IBM

IBM Watson Health and Merge Healthcare are bringing new insights, made possible through artificial intelligence and cognitive computing, to medical imaging.

Dr. Tanveer Syeda-Mahmood developed a tool that uses IBM Watson Health technology to help clinicians detect heart disease. Syeda-Mahmood is an IBM Fellow and chief scientist of the Medical Sieve Radiology Grand Challenge Project at IBM Research.

Radiologists are about to get some help with their imaging workload.

IBM Watson Health and Merge Healthcare, an IBM Company, are showcasing new tools to help clinicians analyze medical images. The offerings use machine learning, artificial intelligence, and cognitive computing to offer additional information that can help tailor diagnosis and treatment decisions.

To deliver physicians a better understanding of the IBM technology, IBM Research is also conducting a live demonstration of the tools at the Radiological Society of North America Annual Meeting (RSNA) in Chicago, according to a press release.

The release notes that at least 90% of all medical data is images, according to IBM researchers' estimates, and that medical images are growing at the fastest rate of any type of medical data. Accuracy can suffer in the face of all these images that need to be analyzed, referenced, and compared by humans.

An oft-cited Johns Hopkins study published in 2013 revealed how frequently diagnostic errors happen and how devastating they can be. Researches estimated that 80,000-160,000 U.S. patients experience permanent injury or death related to misdiagnosis each year. 

"We designed this Watson-based demonstration to show physicians that soon they can navigate an abundance of digital data--structured and unstructured, text and images--and make informed decisions based on relevant and current information," Dr. Tanveer Syeda-Mahmood, an IBM Fellow and chief scientist of the Medical Sieve Radiology Grand Challenge Project at IBM Research, said in an IBM Research blog post. "More importantly, we can analyze a broad array of medical data and derive Watson-powered insights that are meaningful to doctors."

Syeda-Mahmood had a personal reason for her interest in using Watson to help analyze medical images. According to an IBM profile of the researcher, her father suffered a hemorrhagic stroke that was misdiagnosed as an ischemic stroke. He was given blood thinners as a result of this mistaken diagnosis. His condition worsened and he went into a coma. Happily, her father eventually recovered after medical repatriation to India and treatment there.

According to the blog post, that experience drove Syeda-Mahmood to research ways to enable more accurate diagnoses. 

At RSNA, Watson Health and Merge will both showcase new offerings, according to the press release. Watson Health will debut a cognitive peer review tool to clarify differences between a patient's health record and clinical evidence; a cognitive data summarization tool offering personalized patient information for interpretation, diagnosis, and treatment decisions; a cognitive physician support tool to enable personalized decisions using the entirety of patient data; and the MedyMatch "Brain Bleed" App to help diagnose a trauma patient with brain bleed or stroke.

The release also details the products Merge will show, including Marktation, a tool that enables faster image interpretation and will be used first in mammography; Watson Clinical Integration Module, a cloud application that radiologists can use to Strengthen efficiency and reduce errors; and the Lesion Segmentation and Tracking Module, to allow faster interpretation and reporting of comparison exams.

"Watson cognitive computing is ideally suited to support radiologists on their journey 'Beyond Imaging' to practices that address the needs of patient populations, deliver improved patient outcomes, and demonstrate real-world value," said Nancy Koenig, general manager of Merge Healthcare, in the release. "This week at RSNA, Merge is proud to unveil solutions for providers that enable the first steps on the cognitive care journey, addressing breast cancer, lung cancer, and trauma patients in the ER."     

[Image courtesy of IBM RESEARCH]

Sun, 24 Jul 2022 12:00:00 -0500 en text/html https://www.mddionline.com/radiological/medical-imaging-powered-ibm
Killexams : Vocal Biomarkers Market Is Growing Worldwide 2022 2028 | Beyond Verbal, Sonde Health, Sharecare, IBM Coporation

(MENAFN- EIN Presswire)

Vocal

SEATTLE, UNITED STATES, UNITED STATES, August 5, 2022 /EINPresswire.com / -- New Research Study“”Vocal Biomarkers Market 2022 analysis by Market Growth (Drivers, Constraints, Opportunities, Threats, Challenges and Business Opportunities), Size, Share and Outlook“” has been added to Coherent Market Insights. The study examines the worldwide Vocal Biomarkers industry growth rate and market value in light of market dynamics and growth-inducing variables. The research covers every aspect of the industry, from regional development to prospective market growth rates. The research gives a complete assessment of the market, market size, geographical overview, and profit predictions for the industry. It includes revenue models, competitive spectra, and vendor strategies defined by significant vendors and industry participants.

The study focuses on the size of the Vocal Biomarkers market, current trends and development status, investment possibilities, market dynamics (e.g., driving drivers, growth factors), and industry news (e.g. mergers, acquisitions and investments). Technological improvements and innovations will further enhance the product's performance, allowing it to be employed in more downstream applications. Furthermore, Porter's five force analyses (possible entrants, suppliers, substitutes, customers, and industry rivals) are useful in understand the Vocal Biomarkers market.

Request for trial Report @

Competitive Landscape

The report studies the Vocal Biomarkers market size by player, region, product type and final industry, historical data 2016-2020 and forecast data 2022-2028; the report also studies the global market competitive environment, market drivers and trends, opportunities and challenges, risks and barriers to entry, sales channels, distributors and porters.

Leading Vocal Biomarkers Market Players are as followed:

• Beyond Verbal, Inc.*
• Sonde Health
• Sharecare, Inc.
• IBM Coporation
• Cogito Corporation

Market segmentation of Vocal Biomarkers market:

Vocal Biomarkers market is divided by type and application. For the period 2022-2028, cross-segment growth provides accurate calculations and forecasts of sales by Type and Application in terms of volume and value. This analysis can help you grow your business by targeting qualified niche markets.

Get PDF Brochure With Latest Insights @

Regional Outlook:

The Asia Pacific, North America, Europe, Latin America, and the Rest of the World are examined in the geographical analysis of the worldwide Vocal Biomarkers market. Because of its well-established Healthcare service providers and big consumer base, North America is the world's leading/significant area in terms of market share. Over the projected period 2022-2028, Asia-Pacific is expected to have the greatest growth rate/CAGR.

Method of Research

The report provides first-hand information performed by key players using quantitative & qualitative assessment as per the parameters of the Porter's Five Force Model. It throws light on the macro-economic indicators, parent market trends, and growth factors. Primary (surveys, interviews, and questionnaires) & secondary researches (SEC filings, white paper references, and published reports) have been carried out to provide a better understanding of the market. The data used in the report has passed multi-step verification to assure both the authenticity as well as the quality of the insight that is provided. Bottom-up & top-down approaches are also used for ensuring the credibility of the valuations and market segments.

The following are the study objectives for this report:

✔SWOT Analysis focuses on worldwide main manufacturers to define, assess, and analyse market competition. By kind, application, and region, the market is defined, described, and forecasted.
✔Examine the global and main regional market potential and advantage, opportunity and challenge, constraints and risks.
✔Determine whether trends and factors are driving or limiting market growth.
✔By identifying high-growth categories, stakeholders would be able to analyse market potential.
✔Conduct a strategic study of each submarket's growth trends and market contribution.
✔Expansions, agreements, new product launches, and acquisitions in the market are all examples of competitive developments.
✔To create a strategic profile of the main players and analyse their growth plans in depth.

Buy This Complete Business Report @

Table of Contents with Major Points:

1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2022-2028 (USD Billion)
1.2.1. Vocal Biomarkers Market, by Region, 2022-2028 (USD Billion)
1.2.2. Vocal Biomarkers Market, by Type, 2022-2028 (USD Billion)
1.2.3. Vocal Biomarkers Market, by Application, 2022-2028 (USD Billion)
1.2.4. Vocal Biomarkers Market, by Verticles, 2022-2028 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption

2. Global Vocal Biomarkers Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates

3. Global Vocal Biomarkers Market Dynamics
3.1. Vocal Biomarkers Market Impact Analysis (2022-2028)
3.1.1. Market Drivers
3.1.2. Market Challenges
3.1.3. Market Opportunities

4. Global Vocal Biomarkers Market Industry Analysis
4.1. Porter's 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter's 5 Force Model (2022-2028)
4.2. PEST Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.3. Investment Adoption Model
4.4. Analyst Recommendation & Conclusion

5. Global Vocal Biomarkers Market, by Type
5.1. Market Snapshot
5.2. Global Vocal Biomarkers Market by Type, Performance – Potential Analysis
5.3. Global Vocal Biomarkers Market Estimates & Forecasts by Type 2022-2028 (USD Billion)
5.4. Vocal Biomarkers Market, Sub Segment Analysis

6. Global Vocal Biomarkers Market, by Application
6.1. Market Snapshot
6.2. Global Vocal Biomarkers Market by Application, Performance – Potential Analysis
6.3. Global Vocal Biomarkers Market Estimates & Forecasts by Application 2022-2028 (USD Billion)
6.4. Vocal Biomarkers Market, Sub Segment Analysis
6.4.1. Others

7. Global Vocal Biomarkers Market, by Verticles
7.1. Market Snapshot
7.2. Global Vocal Biomarkers Market by Verticles, Performance – Potential Analysis
7.3. Global Vocal Biomarkers Market Estimates & Forecasts by Verticles 2022-2028 (USD Billion)
7.4. Vocal Biomarkers Market, Sub Segment Analysis

8. Global Vocal Biomarkers Market, Regional Analysis
8.1. Vocal Biomarkers Market, Regional Market Snapshot
8.2. North America Vocal Biomarkers Market
8.3. Europe Vocal Biomarkers Market Snapshot
8.4. Asia-Pacific Vocal Biomarkers Market Snapshot
8.5. Latin America Vocal Biomarkers Market Snapshot
8.6. Rest of The World Vocal Biomarkers Market

9. Competitive Intelligence
9.1. Top Market Strategies
9.2. Company Profiles
9.2.1. Keyplayer1
9.2.1.1. Key InDurationation
9.2.1.2. Overview
9.2.1.3. Financial (Subject to Data Availability)
9.2.1.4. Product Summary
9.2.1.5. latest Developments

10. Research Process
10.1. Research Process
10.1.1. Data Mining
10.1.2. Analysis
10.1.3. Market Estimation
10.1.4. Validation
10.1.5. Publishing
10.2. Research Attributes

Thank you for taking the time to read the research report. Kindly inform us for additional information about the customized report and customization plan, and we will provide you the most appropriate customized report.


About Us:

Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email:

Mr.Shah
Coherent Market Insights
+1 2067016702
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn

MENAFN05082022003118003196ID1104652952


Fri, 05 Aug 2022 05:12:00 -0500 Date text/html https://menafn.com/1104652952/Vocal-Biomarkers-Market-Is-Growing-Worldwide-2022-2028-Beyond-Verbal-Sonde-Health-Sharecare-IBM-Coporation
Killexams : IBM RELEASES SECOND QUARTER RESULTS

Growth Across Key Segments Led by Hybrid Cloud Adoption; Solid Cash and Profit Generation

ARMONK, N.Y., July 18, 2022 /PRNewswire/ -- IBM (NYSE: IBM) today announced second-quarter 2022 earnings results.

IBM Corporation logo. (PRNewsfoto/IBM)

"In the quarter we delivered good revenue performance with balanced growth across our geographies, driven by client demand for our hybrid cloud and AI offerings. The IBM team executed our strategy well," said Arvind Krishna, IBM chairman and chief executive officer. "With our first half results, we continue to expect full-year revenue growth at the high end of our mid-single digit model."

Second-Quarter Highlights

  • Revenue
    - Revenue of $15.5 billion, up 9 percent, up 16 percent at constant currency (about 5 points from sales to Kyndryl)
    - Software revenue up 6 percent, up 12 percent at constant currency (about 7 points from sales to Kyndryl)
    - Consulting revenue up 10 percent, up 18 percent at constant currency
    - Infrastructure revenue up 19 percent, up 25 percent at constant currency (about 7 points from sales to Kyndryl)
    - Hybrid cloud revenue, over the last 12 months, of $21.7 billion, up 16 percent, up 19 percent at constant currency
  • Cash Flow
    - On a consolidated basis, year to date, net cash from operating activities of $4.6 billion; free cash flow of $3.3 billion 
SECOND QUARTER 2022 INCOME STATEMENT SUMMARY
Pre-tax 
Gross Pre-tax  Income  Net  Diluted 
Revenue Profit Income Margin Income EPS
GAAP from
Continuing
Operations
$ 15.5B $ 8.3B $ 1.7B 11.1 % $ 1.5B $ 1.61
    Year/Year 9 %* 6 % 89 % 4.7 Pts 81 % 79 %
Operating
(Non-GAAP)
$ 8.5B $ 2.5B 16.2 % $ 2.1B $ 2.31
    Year/Year 5 % 48 % 4.2 Pts 45 % 43 %
*16% at constant currency

"We are a faster-growing, focused, disciplined company with sound business fundamentals," said James Kavanaugh, IBM senior vice president and chief financial officer. "Our recurring revenue stream and solid cash generation position us well to continue to invest in R&D, acquire new companies, and strengthen our talent in every part of the business, while also returning value to shareholders through our dividend."

Segment Results for Second Quarter

  • Software (includes Hybrid Platform & Solutions, Transaction Processing)— revenues of $6.2 billion, up 6.4 percent, up 11.6 percent at constant currency (about 7 points from sales to Kyndryl):
    - Hybrid Platform & Solutions up 4 percent, up 9 percent at constant currency (about 1.5 points from sales to Kyndryl):
       -- Red Hat up 12 percent, up 17 percent at constant currency
       -- Automation up 4 percent, up 8 percent at constant currency
       -- Data & AI flat, up 4 percent at constant currency
       -- Security flat, up 5 percent at constant currency
    - Transaction Processing up 12 percent, up 19 percent at constant currency (about 22 points from sales to Kyndryl)
    - Software segment hybrid cloud revenue up 14 percent, up 18 percent at constant currency
  • Consulting (includes Business Transformation, Technology Consulting and Application Operations)— revenues of $4.8 billion, up 9.8 percent, up 17.8 percent at constant currency:
    - Business Transformation up 9 percent, up 16 percent at constant currency
    - Technology Consulting up 14 percent, up 23 percent at constant currency
    - Application Operations up 9 percent, up 17 percent at constant currency
    - Consulting segment hybrid cloud revenue up 20 percent, up 29 percent at constant currency
  • Infrastructure (includes Hybrid Infrastructure, Infrastructure Support)— revenues of $4.2 billion, up 19.0 percent, up 25.4 percent at constant currency (about 7 points from sales to Kyndryl):
    - Hybrid Infrastructure up 34 percent, up 41 percent at constant currency (about 7 points from sales to Kyndryl)
       -- IBM z Systems up 69 percent, up 77 percent at constant currency
       -- Distributed Infrastructure up 11 percent, up 17 percent at constant currency
    - Infrastructure Support down 2 percent, up 5 percent at constant currency (about 8 points from sales to Kyndryl)
    - Infrastructure segment hybrid cloud revenue up 24 percent, up 30 percent at constant currency
  • Financing (includes client and commercial financing)— revenues of $0.1 billion, down 29.9 percent, down 26.6 percent at constant currency

Cash Flow and Balance Sheet
On a consolidated basis, in the second quarter, the company generated net cash from operating activities of $1.3 billion or $2.6 billion excluding IBM Financing receivables. IBM's free cash flow was $2.1 billion. The company returned $1.5 billion to shareholders in dividends in the second quarter.

On a consolidated basis, for the first six months of the year, the company generated net cash from operating activities of $4.6 billion or $4.2 billion excluding IBM Financing receivables. IBM's free cash flow was $3.3 billion, which includes cash impacts from the company's structural actions initiated at the end of 2020.

IBM ended the second quarter with $7.8 billion of cash on hand (which includes marketable securities), up $0.2 billion from year-end 2021. Debt, including IBM Financing debt of $12.3 billion, totaled $50.3 billion, down $1.4 billion since the end of 2021.

Full-Year 2022 Expectations

  • Revenue growth: The company continues to expect constant currency revenue growth at the high end of its mid-single digit model. The company also expects an additional 3.5 point contribution from incremental sales to Kyndryl. At mid-July 2022 foreign exchange rates, currency is expected to be about a six-point headwind.
  • Free Cash Flow: The company now expects about $10 billion in consolidated free cash flow.

Forward-Looking and Cautionary Statements
Except for the historical information and discussions contained herein, statements contained in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on the company's current assumptions regarding future business and financial performance. These statements involve a number of risks, uncertainties and other factors that could cause real results to differ materially, including, but not limited to, the following: a downturn in economic environment and client spending budgets; a failure of the company's innovation initiatives; damage to the company's reputation; risks from investing in growth opportunities; failure of the company's intellectual property portfolio to prevent competitive offerings and the failure of the company to obtain necessary licenses; the company's ability to successfully manage acquisitions, alliances and dispositions, including integration challenges, failure to achieve objectives, the assumption of liabilities, and higher debt levels; fluctuations in financial results; impact of local legal, economic, political, health and other conditions; the company's failure to meet growth and productivity objectives; ineffective internal controls; the company's use of accounting estimates; impairment of the company's goodwill or amortizable intangible assets; the company's ability to attract and retain key employees and its reliance on critical skills; impacts of relationships with critical suppliers; product quality issues; impacts of business with government clients; reliance on third party distribution channels and ecosystems; cybersecurity and data privacy considerations; adverse effects related to climate change and environmental matters, tax matters; legal proceedings and investigatory risks; the company's pension plans; currency fluctuations and customer financing risks; impact of changes in market liquidity conditions and customer credit risk on receivables; potential failure of the separation of Kyndryl Holdings, Inc. to qualify for tax-free treatment; risk factors related to IBM securities; and other risks, uncertainties and factors discussed in the company's Form 10-Qs, Form 10-K and in the company's other filings with the U.S. Securities and Exchange Commission or in materials incorporated therein by reference. Any forward-looking statement in this release speaks only as of the date on which it is made. Except as required by law, the company assumes no obligation to update or revise any forward-looking statements.

Presentation of Information in this Press Release
On November 3, 2021, IBM completed the separation of Kyndryl. Unless otherwise specified, results are presented on a continuing operations basis. All references to revenue impacts from sales to Kyndryl are incremental sales post-separation.

In an effort to provide investors with additional information regarding the company's results as determined by generally accepted accounting principles (GAAP), the company has also disclosed in this press release the following non-GAAP information, which management believes provides useful information to investors: 

IBM results —

  • adjusting for currency (i.e., at constant currency);
  • presenting operating (non-GAAP) earnings per share amounts and related income statement items;
  • consolidated free cash flow;
  • consolidated cash from operating activities excluding IBM Financing receivables;

The rationale for management's use of these non-GAAP measures is included in Exhibit 99.2 in the Form 8‑K that includes this press release and is being submitted today to the SEC.

Conference Call and Webcast
IBM's regular quarterly earnings conference call is scheduled to begin at 5:00 p.m. EDT, today. The Webcast may be accessed via a link at https://www.ibm.com/investor/events/earnings-2q22. Presentation charts will be available shortly before the Webcast.

Financial Results Below (certain amounts may not add due to use of rounded numbers; percentages presented are calculated from the underlying whole-dollar amounts).

Contact:       IBM
                    Sarah Meron, 347 891 1770
                    sarah.meron@ibm.com 
    
                    Tim Davidson, 914 844 7847
                    tfdavids@us.ibm.com  

 

INTERNATIONAL BUSINESS MACHINES CORPORATION COMPARATIVE FINANCIAL RESULTS (Unaudited; Dollars in millions except per share amounts)
Three Months Ended Six Months Ended
June 30,  June 30, 
2022 2021* 2022 2021*
REVENUE
Software $ 6,166 $ 5,795 $ 11,938 $ 10,933
Consulting 4,809 4,378 9,637 8,641
Infrastructure 4,235 3,560 7,453 6,853
Financing 146 209 300 417
Other 180 277 404 561
TOTAL REVENUE 15,535 14,218 29,732 27,405
GROSS PROFIT 8,290 7,852 15,625 14,879
GROSS PROFIT MARGIN
Software 79.2 % 79.7 % 79.0 % 78.8 %
Consulting 24.2 % 27.6 % 24.3 % 27.7 %
Infrastructure 53.8 % 57.1 % 52.4 % 56.7 %
Financing 35.3 % 29.9 % 36.5 % 32.7 %
TOTAL GROSS PROFIT MARGIN 53.4 % 55.2 % 52.6 % 54.3 %
EXPENSE AND OTHER INCOME
S,G&A 4,855 4,849 9,452 9,536
R,D&E 1,673 1,641 3,352 3,257
Intellectual property and custom development income (176) (133) (297) (278)
Other (income) and expense (81) 302 166 647
Interest expense 297 281 607 561
TOTAL EXPENSE AND OTHER INCOME 6,568 6,940 13,280 13,724
INCOME/(LOSS) FROM CONTINUING OPERATIONS
BEFORE INCOME TAXES 1,722 912 2,345 1,155
Pre-tax margin 11.1 % 6.4 % 7.9 % 4.2 %
Provision for/(Benefit from) income taxes 257 101 218 (58)
Effective tax rate 14.9 % 11.1 % 9.3 % (5.0) %
INCOME FROM CONTINUING OPERATIONS $ 1,465 $ 810 $ 2,127 $ 1,213
DISCONTINUED OPERATIONS
Income/(Loss) from discontinued operations, net of taxes (73) 515 (2) 1,067
NET INCOME $ 1,392 $ 1,325 $ 2,125 $ 2,280
EARNINGS/(LOSS) PER SHARE OF COMMON STOCK
Assuming Dilution
Continuing Operations $ 1.61 $ 0.90 $ 2.34 $ 1.34
Discontinued Operations $ (0.08) $ 0.57 $ 0.00 $ 1.18
TOTAL $ 1.53 $ 1.47 $ 2.34 $ 2.52
Basic
Continuing Operations $ 1.62 $ 0.91 $ 2.36 $ 1.36
Discontinued Operations $ (0.08) $ 0.57 $ 0.00 $ 1.19
TOTAL $ 1.54 $ 1.48 $ 2.36 $ 2.55
WEIGHTED-AVERAGE NUMBER OF COMMON SHARES OUTSTANDING (M's)
Assuming Dilution 910.7 904.2 910.0 903.0
Basic 901.5 895.0 900.4 894.3
____________________
* Recast to conform with 2022 presentation.

 

INTERNATIONAL BUSINESS MACHINES CORPORATION CONDENSED CONSOLIDATED BALANCE SHEET (Unaudited)
At At
June 30,  December 31, 
(Dollars in Millions) 2022 2021
ASSETS:
Current Assets:
Cash and cash equivalents $ 7,034 $ 6,650
Restricted cash 220 307
Marketable securities 524 600
Notes and accounts receivable - trade, net 5,867 6,754
Short-term financing receivables, net 7,233 8,014
Other accounts receivable, net 909 1,002
Inventories 1,684 1,649
Deferred costs 1,010 1,097
Prepaid expenses and other current assets 3,414 3,466
Total Current Assets 27,896 29,539
Property, plant and equipment, net 5,275 5,694
Operating right-of-use assets, net 2,848 3,222
Long-term financing receivables, net 5,316 5,425
Prepaid pension assets 9,930 9,850
Deferred costs 865 924
Deferred taxes 7,073 7,370
Goodwill 55,039 55,643
Intangibles, net 11,571 12,511
Investments and sundry assets 1,689 1,823
Total Assets $ 127,503 $ 132,001
LIABILITIES:
Current Liabilities:
Taxes $ 1,742 $ 2,289
Short-term debt 5,981 6,787
Accounts payable 3,707 3,955
Deferred income 12,522 12,518
Operating lease liabilities 884 974
Other liabilities 7,008 7,097
Total Current Liabilities 31,844 33,619
Long-term debt 44,328 44,917
Retirement related obligations 13,118 14,435
Deferred income 3,069 3,577
Operating lease liabilities 2,182 2,462
Other liabilities 13,486 13,996
Total Liabilities 108,026 113,005
EQUITY:
IBM Stockholders' Equity:
Common stock 57,802 57,319
Retained earnings 153,298 154,209
Treasury stock — at cost (169,522) (169,392)
Accumulated other comprehensive income/(loss) (22,169) (23,234)
Total IBM Stockholders' Equity 19,409 18,901
Noncontrolling interests 67 95
Total Equity 19,476 18,996
Total Liabilities and Equity $ 127,503 $ 132,001

 

INTERNATIONAL BUSINESS MACHINES CORPORATION CASH FLOW ANALYSIS (Unaudited)
Trailing Twelve
Three Months Ended Six Months Ended Months Ended
June 30,  June 30,  June 30, 
(Dollars in Millions) 2022 2021 2022 2021 2022
Consolidated Net Cash from Operations per GAAP $ 1,321 $ 2,625 $ 4,569 $ 7,539 $ 9,826
Less: change in IBM Financing receivables (1,264) 900 367 3,763 511
Capital Expenditures, net (494) (688) (871) (1,217) (2,035)
Consolidated Free Cash Flow 2,091 1,037 3,331 2,559 7,279
Acquisitions (260) (1,747) (958) (2,866) (1,385)
Divestitures 1,207 (10) 1,268 (25) 1,408
Dividends (1,488) (1,467) (2,963) (2,924) (5,907)
Non-Financing Debt (2,934) (586) 1,740 (2,331) 2,880
Other (includes IBM Financing net receivables and debt) (1,607) (335) (2,197) (522) (4,661)
Change in Cash, Cash Equivalents, Restricted Cash and Short-term
Marketable Securities*
$ (2,991) $ (3,108) $ 221 $ (6,110) $ (387)
____________________
* Cash flows are presented on a consolidated basis. 

 

INTERNATIONAL BUSINESS MACHINES CORPORATION CASH FLOW (Unaudited)
Three Months Ended Six Months Ended
June 30,  June 30, 
(Dollars in Millions) 2022 2021 2022 2021
Net Income from Operations $ 1,392 $ 1,325 $ 2,125 $ 2,280
Depreciation/Amortization of Intangibles 1,245 1,680 2,501 3,352
Stock-based Compensation 254 243 488 457
Working Capital / Other (307) (1,524) (912) (2,313)
IBM Financing A/R (1,264) 900 367 3,763
Net Cash Provided by Operating Activities $ 1,321 $ 2,625 $ 4,569 $ 7,539
Capital Expenditures, net of payments & proceeds (494) (688) (871) (1,217)
Divestitures, net of cash transferred 1,207 (10) 1,268 (25)
Acquisitions, net of cash acquired (260) (1,747) (958) (2,866)
Marketable Securities / Other Investments, net (281) (227) (625) (562)
Net Cash Provided by/(Used in) Investing Activities $ 172 $ (2,671) $ (1,186) $ (4,671)
Debt, net of payments & proceeds (2,514) (1,500) 434 (5,799)
Dividends (1,488) (1,467) (2,963) (2,924)
Financing - Other (195) (163) (290) (190)
Net Cash Provided by/(Used in) Financing Activities $ (4,197) $ (3,131) $ (2,819) $ (8,914)
Effect of Exchange Rate changes on Cash (262) 69 (267) (65)
Net Change in Cash, Cash Equivalents and Restricted Cash* $ (2,965) $ (3,108) $ 297 $ (6,110)
____________________
* Cash flows are presented on a consolidated basis. 

 

INTERNATIONAL BUSINESS MACHINES CORPORATION SEGMENT DATA (Unaudited)
Three Months Ended June 30, 2022
(Dollars in Millions) Software Consulting Infrastructure Financing
Revenue $ 6,166 $ 4,809 $ 4,235 $ 146
Pre-tax Income/(Loss) from Continuing Operations $ 1,375 $ 343 $ 757 $ 102
Pre-tax Margin 22.3 % 7.1 % 17.9 % 69.7 %
Change YTY Revenue 6.4 % 9.8 % 19.0 % (29.9) %
Change YTY Revenue - constant currency 11.6 % 17.8 % 25.4 % (26.6) %
Three Months Ended June 30, 2021*
(Dollars in Millions) Software Consulting Infrastructure Financing
Revenue $ 5,795 $ 4,378 $ 3,560 $ 209
Pre-tax Income/(Loss) from Continuing Operations $ 1,059 $ 270 $ 489 $ 131
Pre-tax Margin 18.3 % 6.2 % 13.7 % 63.0 %
____________________
* Recast to conform with 2022 presentation. 
Six Months Ended June 30, 2022
(Dollars in Millions) Software Consulting Infrastructure Financing
Revenue $ 11,938 $ 9,637 $ 7,453 $ 300
Pre-tax Income/(Loss) from Continuing Operations $ 2,509 $ 691 $ 956 $ 186
Pre-tax Margin 21.0 % 7.2 % 12.8 % 62.0 %
Change YTY Revenue 9.2 % 11.5 % 8.8 % (28.0) %
Change YTY Revenue - constant currency 13.4 % 17.6 % 13.4 % (25.5) %
Six Months Ended June 30, 2021*
(Dollars in Millions) Software Consulting Infrastructure Financing
Revenue $ 10,933 $ 8,641 $ 6,853 $ 417
Pre-tax Income/(Loss) from Continuing Operations $ 1,717 $ 547 $ 780 $ 229
Pre-tax Margin 15.7 % 6.3 % 11.4 % 55.0 %
____________________
* Recast to conform with 2022 presentation.

 

INTERNATIONAL BUSINESS MACHINES CORPORATION U.S. GAAP TO OPERATING (Non-GAAP) RESULTS RECONCILIATION (Unaudited; Dollars in millions except per share amounts)
Three Months Ended June 30, 2022
Continuing Operations
Acquisition- Retirement- Tax Kyndryl-
Related Related Reform Related Operating
GAAP Adjustments Adjustments Impacts Impacts (Non-GAAP)
Gross Profit $ 8,290 $ 180 $ $ $ $ 8,470
Gross Profit Margin 53.4 % 1.2  pts.    pts.    pts.    pts.   54.5 %
S,G&A $ 4,855 $ (279) $ $ $ (0) $ 4,576
Other (Income) & Expense (81) (1) (192) (145) (418)
Total Expense & Other (Income) 6,568 (280) (192) (145) 5,952
Pre-tax Income from Continuing 1,722 460 192 145 2,518
Pre-tax Income Margin from 11.1 % 3.0  pts.   1.2  pts.    pts.   0.9  pts.   16.2 %
Provision for/(Benefit from) Income $ 257 $ 115 $ 46 $ (4) $ $ 413
Effective Tax Rate 14.9 % 1.8  pts.   0.7  pts.   (0.2)  pts.   (0.9)  pts.   16.4 %
Income from Continuing Operations $ 1,465 $ 345 $ 146 $ 4 $ 145 $ 2,105
Income Margin from Continuing 9.4 % 2.2  pts.   0.9  pts.   0.0  pts.   0.9  pts.   13.5 %
Diluted Earnings/(Loss) Per Share: $ 1.61 $ 0.38 $ 0.16 $ 0.00 $ 0.16 $ 2.31
Three Months Ended June 30, 2021
Continuing Operations
Acquisition- Retirement- Tax Kyndryl-
Related Related Reform Related Operating
GAAP Adjustments Adjustments Impacts Impacts (Non-GAAP)
Gross Profit $ 7,852 $ 179 $ $ $ $ 8,031
Gross Profit Margin 55.2 % 1.3  pts.    pts.    pts.    pts.   56.5 %
S,G&A $ 4,849 $ (294) $ $ $ $ 4,555
Other (Income) & Expense 302 (1) (317) (16)
Total Expense & Other (Income) 6,940 (294) (317) 6,329
Pre-tax Income/(Loss) from Continuing 912 474 317 1,702
Pre-tax Income Margin from 6.4 % 3.3  pts.   2.2  pts.    pts.    pts.   12.0 %
Provision for/(Benefit from) Income $ 101 $ 105 $ 53 $ (14) $ $ 246
Effective Tax Rate 11.1 % 3.1  pts.   1.0  pts.   (0.8)  pts.    pts.   14.5 %
Income from Continuing Operations $ 810 $ 368 $ 264 $ 14 $ $ 1,456
Income Margin from Continuing 5.7 % 2.6  pts.   1.9  pts.   0.1  pts.    pts.   10.2 %
Diluted Earnings/(Loss) Per Share: $ 0.90 $ 0.41 $ 0.29 $ 0.01 $ $ 1.61
____________________
(1)  Includes amortization of purchased intangible assets, in process R&D, transaction costs, applicable restructuring and related expenses, tax charges related to acquisition
(2)  Includes amortization of prior service costs, interest cost, expected return on plan assets, amortized actuarial gains/losses, the impacts of any plan curtailments/
(3)  Primarily relates to the fair value changes in the retained Kyndryl common stock and the related cash-settled swap.
(4)  Tax impact on operating (non-GAAP) pre-tax income from continuing operations is calculated under the same accounting principles applied to the As Reported pre-tax

 

INTERNATIONAL BUSINESS MACHINES CORPORATION U.S. GAAP TO OPERATING (Non-GAAP) RESULTS RECONCILIATION (Unaudited; Dollars in millions except per share amounts)
Six Months Ended June 30, 2022
Continuing Operations
Acquisition- Retirement- Tax Kyndryl-
Related Related Reform Related Operating
GAAP Adjustments Adjustments Impacts Impacts (Non-GAAP)
Gross Profit $ 15,625 $ 361 $ $ $ $ 15,986
Gross Profit Margin 52.6 % 1.2  pts.    pts.    pts.    pts.   53.8 %
S,G&A $ 9,452 $ (565) $ $ $ (0) $ 8,887
Other (Income) & Expense 166 (1) (394) (367) (596)
Total Expense & Other (Income) 13,280 (566) (394) (367) 11,953
Pre-tax Income from Continuing 2,345 928 394 367 4,033
Pre-tax Income Margin from 7.9 % 3.1  pts.   1.3  pts.    pts.   1.2  pts.   13.6 %
Provision for/(Benefit from) Income $ 218 $ 224 $ 104 $ 112 $ $ 657
Effective Tax Rate 9.3 % 3.4  pts.   1.7  pts.   2.8  pts.   (0.8)  pts.   16.3 %
Income from Continuing Operations $ 2,127 $ 704 $ 290 $ (112) $ 367 $ 3,376
Income Margin from Continuing 7.2 % 2.4  pts.   1.0  pts.   (0.4)  pts.   1.2  pts.   11.4 %
Diluted Earnings/(Loss) Per Share: $ 2.34 $ 0.77 $ 0.32 $ (0.12) $ 0.40 $ 3.71
Six Months Ended June 30, 2021
Continuing Operations
Acquisition- Retirement- Tax Kyndryl-
Related Related Reform Related Operating
GAAP Adjustments Adjustments Impacts Impacts (Non-GAAP)
Gross Profit $ 14,879 $ 353 $ $ $ $ 15,232
Gross Profit Margin 54.3 % 1.3  pts.    pts.    pts.    pts.   55.6 %
S,G&A $ 9,536 $ (582) $ $ $ $ 8,954
Other (Income) & Expense 647 (1) (649) (3)
Total Expense & Other (Income) 13,724 (583) (649) 12,491
Pre-tax Income from Continuing 1,155 936 649 2,741
Pre-tax Income Margin from 4.2 % 3.4  pts.   2.4  pts.    pts.    pts.   10.0 %
Provision for/(Benefit from) Income $ (58) $ 238 $ 86 $ 6 $ $ 272
Effective Tax Rate (5.0) % 10.4  pts.   4.3  pts.   0.2  pts.    pts.   9.9 %
Income from Continuing Operations $ 1,213 $ 699 $ 563 $ (6) $ $ 2,469
Income Margin from Continuing 4.4 % 2.5  pts.   2.1  pts.   (0.0)  pts.    pts.   9.0 %
Diluted Earnings/(Loss) Per Share: $ 1.34 $ 0.77 $ 0.62 $ (0.01) $ $ 2.73
____________________
(1)  Includes amortization of purchased intangible assets, in process R&D, transaction costs, applicable restructuring and related expenses, tax charges related
(2)  Includes amortization of prior service costs, interest cost, expected return on plan assets, amortized actuarial gains/losses, the impacts of any plan
(3)  Primarily relates to the fair value changes in the retained Kyndryl common stock and the related cash-settled swap.
(4)  Tax impact on operating (non-GAAP) pre-tax income from continuing operations is calculated under the same accounting principles applied to the As

 

 

Cision View original content to get multimedia:https://www.prnewswire.com/news-releases/ibm-releases-second-quarter-results-301588504.html

SOURCE IBM

Mon, 18 Jul 2022 08:10:00 -0500 en text/html https://markets.businessinsider.com/news/stocks/ibm-releases-second-quarter-results-1031594969
Killexams : IBM Annual Cost of Data Breach Report 2022: Record Costs Usually Passed On to Consumers, “Long Breach” Expenses Make Up Half of Total Damage

IBM’s annual Cost of Data Breach Report for 2022 is packed with revelations, and as usual none of them are good news. Headlining the report is the record-setting cost of data breaches, with the global average now at $4.35 million. The report also reveals that much of that expense comes with the data breach version of “long Covid,” expenses that are realized more than a year after the attack.

Most organizations (60%) are passing these added costs on to consumers in the form of higher prices. And while 83% of organizations now report experiencing at least one data breach, only a small minority are adopting zero trust strategies.

Security AI and automation greatly reduces expected damage

The IBM report draws on input from 550 global organizations surveyed about the period between March 2021 and March 2022, in partnership with the Ponemon Institute.

Though the average cost of a data breach is up, it is only by about 2.6%; the average in 2021 was $4.24 million. This represents a total climb of 13% since 2020, however, reflecting the general spike in cyber crime seen during the pandemic years.

Organizations are also increasingly not opting to absorb the cost of data breaches, with the majority (60%) compensating by raising consumer prices separate from any other latest increases due to inflation or supply chain issues. The report indicates that this may be an underreported upward influence on prices of consumer goods, as 83% of organizations now say that they have been breached at least once.

Brad Hong, Customer Success Manager for Horizon3.ai, sees a potential consumer backlash on the horizon once public awareness of this practice grows: “It’s already a breach of confidence to lose the confidential data of customers, and sure there’s bound to be an organization across those surveyed who genuinely did put in the effort to protect against and curb attacks, but for those who did nothing, those who, instead of creating a disaster recovery plan, just bought cyber insurance to cover the org’s operational losses, and those who simply didn’t care enough to heed the warnings, it’s the coup de grâce to then pass the cost of breaches to the same customers who are now the victims of a data breach. I’d be curious to know what percent of the 60% of organizations who increased the price of their products and services are using the extra revenue for a war chest or to actually reinforce their security—realistically, it’s most likely just being used to fill a gap in lost revenue for shareholders’ sake post-breach. Without government regulations outlining restrictions on passing cost of breach to consumer, at the least, not without the honest & measurable efforts of a corporation as their custodian, what accountability do we all have against that one executive who didn’t want to change his/her password?”

Breach costs also have an increasingly long tail, as nearly half now come over a year after the date of the attack. The largest of these are generally fines that are levied after an investigation, and decisions or settlements in class action lawsuits. While the popular new “double extortion” approach of ransomware attacks can drive long-term costs in this way, the study finds that companies paying ransom demands to settle the problem quickly aren’t necessarily seeing a large amount of overall savings: their average breach cost drops by just $610,000.

Sanjay Raja, VP of Product with Gurucul, expands on how knock-on data breach damage can continue for years: “The follow-up attack effect, as described, is a significant problem as the playbooks and solutions provided to security operations teams are overly broad and lack the necessary context and response actions for proper remediation. For example, shutting down a user or application or adding a firewall block rule or quarantining a network segment to negate an attack is not a sustainable remediation step to protect an organization on an ongoing basis. It starts with a proper threat detection, investigation and response solution. Current SIEMs and XDR solutions lack the variety of data, telemetry and combined analytics to not only identify an attack campaign and even detect variants on previously successful attacks, but also provide the necessary context, accuracy and validation of the attack to build both a precise and complete response that can be trusted. This is an even greater challenge when current solutions cannot handle complex hybrid multi-cloud architectures leading to significant blind spots and false positives at the very start of the security analyst journey.”

Rising cost of data breach not necessarily prompting dramatic security action

In spite of over four out of five organizations now having experienced some sort of data breach, only slightly over 20% of critical infrastructure companies have moved to zero trust strategies to secure their networks. Cloud security is also lagging as well, with a little under half (43%) of all respondents saying that their security practices in this area are either “early stage” or do not yet exist.

Those that have onboarded security automation and AI elements are the only group seeing massive savings: their average cost of data breach is $3.05 million lower. This particular study does not track average ransom demands, but refers to Sophos research that puts the most latest number at $812,000 globally.

The study also notes serious problems with incident response plans, especially troubling in an environment in which the average ransomware attack is now carried out in four days or less and the “time to ransom” has dropped to a matter of hours in some cases. 37% of respondents say that they do not test their incident response plans regularly. 62% say that they are understaffed to meet their cybersecurity needs, and these organizations tend to suffer over half a million more dollars in damages when they are breached.

Of course, cost of data breaches is not distributed evenly by geography or by industry type. Some are taking much bigger hits than others, reflecting trends established in prior reports. The health care industry is now absorbing a little over $10 million in damage per breach, with the average cost of data breach rising by $1 million from 2021. And companies in the United States face greater data breach costs than their counterparts around the world, at over $8 million per incident.

Shawn Surber, VP of Solutions Architecture and Strategy with Tanium, provides some insight into the unique struggles that the health care industry faces in implementing effective cybersecurity: “Healthcare continues to suffer the greatest cost of breaches but has among the lowest spend on cybersecurity of any industry, despite being deemed ‘critical infrastructure.’ The increased vulnerability of healthcare organizations to cyber threats can be traced to outdated IT systems, the lack of robust security controls, and insufficient IT staff, while valuable medical and health data— and the need to pay ransoms quickly to maintain access to that data— make healthcare targets popular and relatively easy to breach. Unlike other industries that can migrate data and sunset old systems, limited IT and security budgets at healthcare orgs make migration difficult and potentially expensive, particularly when an older system provides a small but unique function or houses data necessary for compliance or research, but still doesn’t make the cut to transition to a newer system. Hackers know these weaknesses and exploit them. Additionally, healthcare orgs haven’t sufficiently updated their security strategies and the tools that manufacturers, IT software vendors, and the FDA have made haven’t been robust enough to thwart the more sophisticated techniques of threat actors.”

Familiar incident types also lead the list of the causes of data breaches: compromised credentials (19%), followed by phishing (16%). Breaches initiated by these methods also tended to be a little more costly, at an average of $4.91 million per incident.

Global average cost of #databreach is now $4.35M, up 13% since 2020. Much of that are realized more than a year after the attack, and 60% of organizations are passing the costs on to consumers in the form of higher prices. #cybersecurity #respectdataClick to Tweet

Cutting the cost of data breach

Though the numbers are never as neat and clean as averages would indicate, it would appear that the cost of data breaches is cut dramatically for companies that implement solid automated “deep learning” cybersecurity tools, zero trust systems and regularly tested incident response plans. Mature cloud security programs are also a substantial cost saver.

Mon, 01 Aug 2022 10:00:00 -0500 Scott Ikeda en-US text/html https://www.cpomagazine.com/cyber-security/ibm-annual-cost-of-data-breach-report-2022-record-costs-usually-passed-on-to-consumers-long-breach-expenses-make-up-half-of-total-damage/
Killexams : Healthcare & Medical Analytics Market Size and Growth 2022 Analysis Report by Distribution Status, Players, Market Analysis and Forecast to 2028

The MarketWatch News Department was not involved in the creation of this content.

Aug 08, 2022 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry."

Global “Healthcare and Medical Analytics Market”2022 research report by market size of different segments and countries in latest years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors and challenges which will define the future growth of the market. Additionally, the Healthcare and Medical Analytics market report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and key players.

Get a trial PDF of the Report - https://www.absolutereports.com/enquiry/request-sample/21320597

Market Analysis and Insights: Global Healthcare and Medical Analytics Market

The global Healthcare and Medical Analytics market size is projected to reach USD million by 2028, from USD million in 2021, at a CAGR of during 2022-2028.
Fully considering the economic change by this health crisis, Prescriptive accounting for of the Healthcare and Medical Analytics global market in 2021, is projected to value USD million by 2028, growing at a revised CAGR from 2022 to 2028. While Hospital segment is altered to CAGR throughout this forecast period.
China Healthcare and Medical Analytics market size is valued at USD million in 2021, while the North America and Europe Healthcare and Medical Analytics are USD million and USD million, severally. The proportion of the North America in 2021, while China and Europe are and respectively, and it is predicted that China proportion will reach in 2028, trailing a CAGR of through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR respectively for the next 6-year period. As for the Europe Healthcare and Medical Analytics landscape, Germany is projected to reach USD million by 2028 trailing a CAGR of over the forecast period 2022-2028.

The major players covered in the Healthcare and Medical Analytics market report are:

● IBM ● OptumHealth ● Oracle ● Verisk Analytics ● Elsevier ● MedeAnalytics ● McKesson ● Truven Health ● Allscripts ● Cerner ● SAS

Get a trial Copy of the Healthcare and Medical Analytics Market Report 2022

Global Healthcare and Medical Analytics Market: Drivers and Restrains

The research report has incorporated the analysis of different factors that augment the market’s growth. It constitutes trends, restraints, and drivers that transform the market in either a positive or negative manner. This section also provides the scope of different segments and applications that can potentially influence the market in the future. The detailed information is based on current trends and historic milestones. This section also provides an analysis of the volume of production about the global market and about each type from 2017 to 2028. This section mentions the volume of production by region from 2017 to 2028. Pricing analysis is included in the report according to each type from the year 2017 to 2028, manufacturer from 2017 to 2022, region from 2017 to 2022, and global price from 2017 to 2028.

A thorough evaluation of the restrains included in the report portrays the contrast to drivers and gives room for strategic planning. Factors that overshadow the market growth are pivotal as they can be understood to devise different bends for getting hold of the lucrative opportunities that are present in the ever-growing market. Additionally, insights into market expert’s opinions have been taken to understand the market better.

To Understand How Covid-19 Impact Is Covered in This Report - https://www.absolutereports.com/enquiry/request-covid19/21320597

Global Healthcare and Medical Analytics Market: Segment Analysis

The research report includes specific segments by region (country), by manufacturers, by Type and by Application. Each type provides information about the production during the forecast period of 2017 to 2028. By Application segment also provides consumption during the forecast period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type

● Prescriptive ● Descriptive ● Predictive

Segment by Application

● Hospital ● Clinic ● Other

Healthcare and Medical Analytics Market Key Points:

● Characterize, portray and Forecast Healthcare and Medical Analytics item market by product type, application, manufactures and geographical regions. ● deliver venture outside climate investigation. ● deliver systems to organization to manage the effect of COVID-19. ● deliver market dynamic examination, including market driving variables, market improvement requirements. ● deliver market passage system examination to new players or players who are prepared to enter the market, including market section definition, client investigation, conveyance model, item informing and situating, and cost procedure investigation. ● Stay aware of worldwide market drifts and deliver examination of the effect of the COVID-19 scourge on significant locales of the world. ● Break down the market chances of partners and furnish market pioneers with subtleties of the cutthroat scene.

Inquire or Share Your Questions If Any before the Purchasing This Report - https://www.absolutereports.com/enquiry/pre-order-enquiry/21320597

Geographical Segmentation:

Geographically, this report is segmented into several key regions, with sales, revenue, market share, and Healthcare and Medical Analytics market growth rate in these regions, from 2015 to 2028, covering

● North America (United States, Canada and Mexico) ● Europe (Germany, UK, France, Italy, Russia and Turkey etc.) ● Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia, and Vietnam) ● South America (Brazil etc.) ● Middle East and Africa (Egypt and GCC Countries)

Some of the key questions answered in this report:

● Who are the worldwide key Players of the Healthcare and Medical Analytics Industry? ● How the opposition goes in what was in store connected with Healthcare and Medical Analytics? ● Which is the most driving country in the Healthcare and Medical Analytics industry? ● What are the Healthcare and Medical Analytics market valuable open doors and dangers looked by the manufactures in the worldwide Healthcare and Medical Analytics Industry? ● Which application/end-client or item type might look for gradual development possibilities? What is the portion of the overall industry of each kind and application? ● What centered approach and imperatives are holding the Healthcare and Medical Analytics market? ● What are the various deals, promoting, and dissemination diverts in the worldwide business? ● What are the key market patterns influencing the development of the Healthcare and Medical Analytics market? ● Financial effect on the Healthcare and Medical Analytics business and improvement pattern of the Healthcare and Medical Analytics business?

Purchase this Report (Price 2900 USD for a Single-User License) -https://www.absolutereports.com/purchase/21320597

Detailed TOC of Global Healthcare and Medical Analytics Market Research Report 2022

1 Healthcare and Medical Analytics Market Overview

1.1 Product Overview and Scope

1.2 Segment by Type

1.2.1 Global Market Size Growth Rate Analysis by Type 2022 VS 2028

1.3 Healthcare and Medical Analytics Segment by Application

1.3.1 Global Consumption Comparison by Application: 2022 VS 2028

1.4 Global Market Growth Prospects

1.4.1 Global Revenue Estimates and Forecasts (2017-2028)

1.4.2 Global Production Capacity Estimates and Forecasts (2017-2028)

1.4.3 Global Production Estimates and Forecasts (2017-2028)

1.5 Global Market Size by Region

1.5.1 Global Market Size Estimates and Forecasts by Region: 2017 VS 2021 VS 2028

1.5.2 North America Healthcare and Medical Analytics Estimates and Forecasts (2017-2028)

1.5.3 Europe Estimates and Forecasts (2017-2028)

1.5.4 China Estimates and Forecasts (2017-2028)

1.5.5 Japan Estimates and Forecasts (2017-2028)

2 Healthcare and Medical Analytics Market Competition by Manufacturers

2.1 Global Production Capacity Market Share by Manufacturers (2017-2022)

2.2 Global Revenue Market Share by Manufacturers (2017-2022)

2.3 Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

2.4 Global Average Price by Manufacturers (2017-2022)

2.5 Manufacturers Production Sites, Area Served, Product Types

2.6 Market Competitive Situation and Trends

2.6.1 Market Concentration Rate

2.6.2 Global 5 and 10 Largest Healthcare and Medical Analytics Players Market Share by Revenue

2.6.3 Mergers and Acquisitions, Expansion

3 Healthcare and Medical Analytics Production Capacity by Region

3.1 Global Production Capacity of Healthcare and Medical Analytics Market Share by Region (2017-2022)

3.2 Global Revenue Market Share by Region (2017-2022)

3.3 Global Production Capacity, Revenue, Price and Gross Margin (2017-2022)

3.4 North America Production

3.4.1 North America Production Growth Rate (2017-2022)

3.4.2 North America Production Capacity, Revenue, Price and Gross Margin (2017-2022)

3.5 Europe Production

3.5.1 Europe Production Growth Rate (2017-2022)

3.5.2 Europe Production Capacity, Revenue, Price and Gross Margin (2017-2022)

3.6 China Production

3.6.1 China Production Growth Rate (2017-2022)

3.6.2 China Production Capacity, Revenue, Price and Gross Margin (2017-2022)

3.7 Japan Production

3.7.1 Japan Production Growth Rate (2017-2022)

3.7.2 Japan Production Capacity, Revenue, Price and Gross Margin (2017-2022)

4 Global Healthcare and Medical Analytics Market Consumption by Region

4.1 Global Consumption by Region

4.1.1 Global Consumption by Region

4.1.2 Global Consumption Market Share by Region

4.2 North America

4.2.1 North America Consumption by Country

4.2.2 United States

4.2.3 Canada

4.3 Europe

4.3.1 Europe Consumption by Country

4.3.2 Germany

4.3.3 France

4.3.4 U.K.

4.3.5 Italy

4.3.6 Russia

4.4 Asia Pacific

4.4.1 Asia Pacific Consumption by Region

4.4.2 China

4.4.3 Japan

4.4.4 South Korea

4.4.5 China Taiwan

4.4.6 Southeast Asia

4.4.7 India

4.4.8 Australia

4.5 Latin America

4.5.1 Latin America Consumption by Country

4.5.2 Mexico

4.5.3 Brazil

Get a trial Copy of the Healthcare and Medical Analytics Market Report 2022

5 Healthcare and Medical Analytics Market Segment by Type

5.1 Global Production Market Share by Type (2017-2022)

5.2 Global Revenue Market Share by Type (2017-2022)

5.3 Global Price by Type (2017-2022)

6 Healthcare and Medical Analytics Market Segment by Application

6.1 Global Production Market Share by Application (2017-2022)

6.2 Global Revenue Market Share by Application (2017-2022)

6.3 Global Price by Application (2017-2022)

7 Healthcare and Medical Analytics Market Key Companies Profiled

7.1 Manufacture 1

7.1.1 Manufacture 1 Corporation Information

7.1.2 Manufacture 1 Product Portfolio

7.1.3 Manufacture 1 Production Capacity, Revenue, Price and Gross Margin (2017-2022)

7.1.4 Manufacture 1 Main Business and Markets Served

7.1.5 Manufacture 1 latest Developments/Updates

7.2 Manufacture 2

7.2.1 Manufacture 2 Corporation Information

7.2.2 Manufacture 2 Product Portfolio

7.2.3 Manufacture 2 Production Capacity, Revenue, Price and Gross Margin (2017-2022)

7.2.4 Manufacture 2 Main Business and Markets Served

7.2.5 Manufacture 2 latest Developments/Updates

7.3 Manufacture 3

7.3.1 Manufacture 3 Corporation Information

7.3.2 Manufacture 3 Product Portfolio

7.3.3 Manufacture 3 Production Capacity, Revenue, Price and Gross Margin (2017-2022)

7.3.4 Manufacture 3 Main Business and Markets Served

7.3.5 Manufacture 3 latest Developments/Updates

8 Healthcare and Medical Analytics Manufacturing Cost Analysis

8.1 Key Raw Materials Analysis

8.1.1 Key Raw Materials

8.1.2 Key Suppliers of Raw Materials

8.2 Proportion of Manufacturing Cost Structure

8.3 Manufacturing Process Analysis of Healthcare and Medical Analytics

8.4 Healthcare and Medical Analytics Industrial Chain Analysis

9 Marketing Channel, Distributors and Customers

9.1 Marketing Channel

9.2 Healthcare and Medical Analytics Distributors List

9.3 Healthcare and Medical Analytics Customers

10 Market Dynamics

10.1 Healthcare and Medical Analytics Industry Trends

10.2 Healthcare and Medical Analytics Market Drivers

10.3 Healthcare and Medical Analytics Market Challenges

10.4 Healthcare and Medical Analytics Market Restraints

11 Production and Supply Forecast

11.1 Global Forecasted Production of Healthcare and Medical Analytics by Region (2023-2028)

11.2 North America Healthcare and Medical Analytics Production, Revenue Forecast (2023-2028)

11.3 Europe Healthcare and Medical Analytics Production, Revenue Forecast (2023-2028)

11.4 China Healthcare and Medical Analytics Production, Revenue Forecast (2023-2028)

11.5 Japan Healthcare and Medical Analytics Production, Revenue Forecast (2023-2028)

12 Consumption and Demand Forecast

12.1 Global Forecasted Demand Analysis of Healthcare and Medical Analytics

12.2 North America Forecasted Consumption of Healthcare and Medical Analytics by Country

12.3 Europe Market Forecasted Consumption of Healthcare and Medical Analytics by Country

12.4 Asia Pacific Market Forecasted Consumption of Healthcare and Medical Analytics by Region

12.5 Latin America Forecasted Consumption of Healthcare and Medical Analytics by Country

13 Forecast by Type and by Application (2023-2028)

13.1 Global Production, Revenue and Price Forecast by Type (2023-2028)

13.1.1 Global Forecasted Production of Healthcare and Medical Analytics by Type (2023-2028)

13.1.2 Global Forecasted Revenue of Healthcare and Medical Analytics by Type (2023-2028)

13.1.3 Global Forecasted Price of Healthcare and Medical Analytics by Type (2023-2028)

13.2 Global Forecasted Consumption of Healthcare and Medical Analytics by Application (2023-2028)

13.2.1 Global Forecasted Production of Healthcare and Medical Analytics by Application (2023-2028)

13.2.2 Global Forecasted Revenue of Healthcare and Medical Analytics by Application (2023-2028)

13.2.3 Global Forecasted Price of Healthcare and Medical Analytics by Application (2023-2028)

14 Research Finding and Conclusion

15 Methodology and Data Source

15.1 Methodology/Research Approach

15.1.1 Research Programs/Design

15.1.2 Market Size Estimation

15.1.3 Market Breakdown and Data Triangulation

15.2 Data Source

15.2.1 Secondary Sources

15.2.2 Primary Sources

15.3 Author List

15.4 Disclaimer

For Detailed TOC - https://www.absolutereports.com/TOC/21320597#TOC

Contact Us:

Absolute Reports

Phone : US +1 424 253 0807

UK +44 203 239 8187

Email : sales@absolutereports.com

Web : https://www.absolutereports.com

Our Other Reporta:

Global Left Ventricular Dysfunction Drug Market Research Report 2022 (Status and Outlook) by latest Trends, Growth Factors, Market Size, Type and Application, Forecast to 2028

Global Freestanding Bathtub Market Size 2022 Research Analysis by Share, Trend, Future Scope, PESTAL Analysis and Forecast to 2025

Global N-Ethyl Para Base Ester Market Size 2022 Research Analysis by Distribution Status, Players, Types, Applications, Market Status and Forecast 2025

Global Budesonide (BUD) Market Size and Share Research Report 2022 Analysis by Product Types, Trends, Production Capacity Estimates and Forecast to 2028

Global Gate Receiver Market Size Research Report 2022 Detailed Analysis by Growth, Trends, Upcoming Demand, Manufactures and Forecast to 2028

Press Release Distributed by The Express Wire

To view the original version on The Express Wire visit Healthcare & Medical Analytics Market Size and Growth 2022 Analysis Report by Distribution Status, Players, Market Analysis and Forecast to 2028

COMTEX_411820406/2598/2022-08-08T03:05:14

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

The MarketWatch News Department was not involved in the creation of this content.

Sun, 07 Aug 2022 19:05:00 -0500 en-US text/html https://www.marketwatch.com/press-release/healthcare-medical-analytics-market-size-and-growth-2022-analysis-report-by-distribution-status-players-market-analysis-and-forecast-to-2028-2022-08-08
Killexams : Blockchain’s use in healthcare ‘essential’ to protect sensitive data: Zelis CTO

Kali Durgampudi, the chief technology officer of healthcare payments company Zelis, believes that the implementation of blockchain tech is vital for protecting patients’ sensitive data from cybercriminals.

Speaking with Health IT News on Wednesday, Durgampudi noted that some of the biggest issues in healthcare are privacy and data security as the industry works to digitize its “archaic paper-based processes.”

“Blockchain technology has the potential to alleviate many of these concerns,” he said, as he highlighted the importance of utilizing a digital ledger that is “impenetrable” to protect sensitive patient and financial data amid the growing rate of cyberattacks across the globe:

“Since the information cannot be modified or copied, blockchain technology vastly reduces security risks, giving hospital and healthcare IT organizations a much stronger line of defense against cybercriminals.”

Durgampudi went on to note that blockchain tech can also play a key role in healthcare payments, as it can help provide greater transparency and efficiency over current payment models in healthcare. He said the many payers and providers were hesitant to share information via email as emails could go awry and there was no proof of delivery.

“Blockchain provides both payers and providers with complete visibility into the entire lifecycle of a claim, from the patient registering at the front desk to disputing a cost to sending an explanation of benefits,” he added.

Real world use

One of the major companies that has worked on blockchain-based healthcare solutions is multinational tech giant IBM.

The blockchain arm of the company has rolled out several solutions for healthcare such as health credential verification, the “Trust Your Supplier” service to find Tested suppliers and “Blockchain Transparent Supply,” which provides supply chain tracking on temperature-controlled pharmaceuticals.

In March 2021, Cointelegraph reported that IBM was working on a trial of a COVID-19 vaccination passport dubbed the “Excelsior Pass” in partnership with former New York Governor Andrew Cuomo. The passport was designed to be able to verify an individual's vaccination or test results by IBM’s blockchain.

Related: Blockchain without crypto: Adoption of decentralized tech

Another key player in the blockchain-based healthcare space is enterprise blockchain VeChain. In June last year, the project teamed up with Shanghai’s Renji Hospital to launch blockchain-based in-vitro fertilization (IVF) service application.

VeChain also partnered with San Marino in July 2021 to launch a nonfungible token- (NFT)-based vaccination passport that was said to be verifiable worldwide by scanning QR codes tied to the certificate.

David Jia, a blockchain investor with a Ph.D. in neuroscience from Oxford University, echoed similar sentiments to Durgampudi this week.

In a Thursday blog post on Medium, Jia emphasized that blockchain tech could significantly Strengthen drug traceability and verification, along with the data management of clinical trials, patient info and claiming/billing.

“Accuracy in medical records over the long term as well as accessibility is essential, as it is necessary for an individual’s record to be able to be transferred between providers, insurance companies, and certified with relative ease. If medical records are stored on a blockchain, they may be updated safely in almost real-time,” he wrote.